Clinical Research Directory
Browse clinical research sites, groups, and studies.
Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clinical Trial
Sponsor: University of California, San Francisco
Summary
Men who are living with HIV and use stimulants face many challenges and barriers that may interfere with remembering to take their HIV medication. Forgetting to take HIV medication puts men living with HIV at a greater risk of becoming virally unsuppressed. Researchers are doing this study to test if a remote intervention can help participants improve remembering to take their HIV medications and reduce the HIV viral load among men living with HIV who use stimulants.
Official title: Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) mHealth Randomized Controlled Hybrid Type I Effectiveness Implementation Trial
Key Details
Gender
MALE
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
270
Start Date
2026-02-09
Completion Date
2028-07-30
Last Updated
2026-03-13
Healthy Volunteers
No
Interventions
reSTART Objective Adherence Self-Monitoring and Postive Affect mHealth Intervention
The reSTART intervention integrates a mobile health application, a urine tenofovir point-of-care self-test, and adherence feedback with motivational messages to increase HIV medication intake, reduce stimulant use, and improve HIV virologic suppression.
urine tenofovir point-of-care self-test
urine tenofovir point-of-care self-test
Locations (1)
University of California, San Francisco
San Francisco, California, United States